[Netilmicin in the treatment of bacterial respiratory tract infections].
Netilmicin - a semisynthetic aminoglycoside - was administered to 33 patients with the acute or chronic lower respiratory tract or pulmonary infections in a daily dose of 5 mg/kg body weight for 10 days. A principle criterium of patients classification to netilmicin therapy were sensitive bacterial strains either in sputum or in BAL liquid. A significant clinical improvement was noted in 88% of the treated patients. However, elimination of pathogens from the sputum was achieved only in 52% of these patients. No improvement was observed in 4% of the treated patients. No adverse reactions were noted. Netilmicin proved safe and effective antibacterial agent in patients with respiratory infections.
Wandzilak
M
M
Kliniki Alergii i Immunologii.
Głuszko
P
P
Królikowski
W
W
Prokop
A
A
Soja
J
J
Szczeklik
A
A
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy*; D006801:Humans; D008169:Lung Abscess / Q000188:drug therapy*; D008875:Middle Aged; D009428:Netilmicin / Q000627:therapeutic use*; D011014:Pneumonia / Q000188:drug therapy*
D009428:Netilmicin
Netylmycyna w leczeniu bakteryjnych zakazeń układu oddechowego.